Amrize vs CRH Public
AMRZ and CRH side by side, both in materials. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMRZ and CRH compare
CRH Public is the larger company, worth 2.9 times as much as Amrize ($61.4B against $21.2B).
On earnings, CRH Public is cheaper: it trades at 17.4× trailing earnings, against 17.5× for Amrize.
CRH Public grew revenue faster over the last twelve months (5.6% versus 3.5% for Amrize).
Amrize keeps more of each dollar of sales as profit, with a net margin of 10.2% compared with 9.2% at CRH Public.
Both pay dividends: Amrize yields 1.7% and CRH Public 1.3%.
CRH Public scores higher on the StockData Score (15 against 10 for Amrize), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMRZ | CRH |
|---|---|---|
| Size and price | ||
| Market cap | $21.2B | $61.4B |
| Share price | $39.82 | $92.37 |
| Change, 1 year | −18.4% | −16.9% |
| Change, 5 years | – | 85.0% |
| Beta (5Y) | 0.54 | 0.90 |
| Employees | 19K | 83K |
| StockData Score | ||
| Total score | 10 | 15 (better) |
| Valuation score | 3 | 4 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 3 | 3 |
| Dividend score | 1 | 2 (better) |
| Valuation | ||
| P/E | 17.5× | 17.4× (better) |
| P/S | 1.7× | 1.6× (better) |
| P/B | 1.7× (better) | 2.5× |
| EV/EBITDA | 9.7× (better) | 10.1× |
| P/FCF | 19.7× (better) | 24.2× |
| PEG | – | 6.83 |
| FCF yield | 5.1% (better) | 4.1% |
| Fair value | $46.40 | $98.82 |
| Margin of safety | 14.2% (better) | 6.5% |
| Growth | ||
| Revenue growth (TTM) | 3.5% | 5.6% (better) |
| Revenue growth, 5Y average | – | 7.7% |
| Net income growth (TTM) | 8.3% (better) | 4.3% |
| EPS growth (TTM) | 8.6% (better) | 6.0% |
| EPS growth, 5Y average | – | 31.2% |
| Profitability | ||
| Gross margin | 24.8% | 36.2% (better) |
| Operating margin | 15.5% (better) | 13.7% |
| Net margin | 10.2% (better) | 9.2% |
| FCF margin | 8.8% (better) | 6.5% |
| Return on equity | 9.8% | 14.8% (better) |
| Return on invested capital | 9.7% | 10.0% (better) |
| Financial health | ||
| Debt / equity | 0.46 (better) | 0.79 |
| Net debt / EBITDA | 2.00 | 1.91 (better) |
| Interest coverage | 5.3× | 6.3× (better) |
| Current ratio | 1.07 | 1.46 (better) |
| Altman Z-score | 1.96 | 2.70 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 1.7% (better) | 1.3% |
| Years of dividend growth | – | 4 |
| Buyback yield | – | 1.5% |
| Shareholder yield | 1.7% | 2.8% (better) |
| Ownership | ||
| Held by institutions | 48.3% | 84.7% |
| Held by insiders | 7.6% | 0.15% |
| Insider net buying, 12 months | $9.9M (better) | $1.2M |
| Superinvestors holding | 3 | 5 (better) |
| Short interest, % of float | 3.0% | 2.1% |
Go deeper
- AMRZ stock overview
- AMRZ income statement
- AMRZ valuation and score
- CRH stock overview
- CRH income statement
- CRH valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.